ONTX - Onconova Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.3000
-0.0300 (-1.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.3300
Open2.3200
Bid0.0000 x 36900
Ask4.9800 x 2200
Day's Range2.3000 - 2.5150
52 Week Range1.6900 - 11.1700
Volume18,196
Avg. Volume34,636
Market Cap13.797M
Beta (3Y Monthly)3.35
PE Ratio (TTM)N/A
EPS (TTM)-4.3190
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.78
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced two presentations at the 24th Congress of the European Hematology Association being held June 13-16, 2019 in Amsterdam, Netherlands.  Dr. Steven Fruchtman, President & CEO, Dr. Ric Woodman, CMO, and Dr. Ronnee Adesanya, VP Medical Affairs, will be attending the conference.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ONTX earnings conference call or presentation 14-May-19 1:00pm GMT

    Q1 2019 Onconova Therapeutics Inc Earnings Call

  • GlobeNewswire2 months ago

    Onconova Therapeutics Announces Presentations at Three Upcoming Conferences

    Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule, which the Company believes blocks cellular signaling by targeting RAS effector pathways.

  • GlobeNewswire2 months ago

    Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results

    NEWTOWN, Pa., May 14, 2019 -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule.

  • Newtown biopharm firm could reap $50M from Chinese licensing deal
    American City Business Journals2 months ago

    Newtown biopharm firm could reap $50M from Chinese licensing deal

    The licensing deal for rigosertib in Greater China includes $6 million upfront in the form of $2 million cash, the purchase of $2 million in Onconova stock and the placement of $2 million in escrow for clinical development expenses.

  • GlobeNewswire2 months ago

    Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has entered into a license agreement for the Greater China territory with HanX Biopharmaceuticals, Inc. (HanX), a China-based pharmaceutical company focused on the development, registration, and commercialization of novel oncology products in China, to develop and commercialize rigosertib, a novel and targeted anti-cancer compound currently in a Phase 3 study for the treatment of higher-risk MDS (HR-MDS). Under the terms of the agreement, Onconova has granted to HanX (i) an exclusive license to develop and commercialize rigosertib in Greater China and (ii) a non-exclusive license to manufacture rigosertib in Greater China.  In exchange for these rights, HanX will make upfront payments totaling $6 million, $4 million of which are cash payments to Onconova, including a $2 million fee and an investment totaling $2 million in shares purchased at a premium to market.

  • GlobeNewswire2 months ago

    Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results

    Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that the Company will release its first quarter 2019 financial results on Tuesday, May 14, 2019 before the market opens.  The Company will host a conference call on Tuesday, May 14, 2019, at 9 a.m. Eastern Time to discuss these results. The call will also be webcast live.  Please click here to access the webcast on the Investor Relations page of the Company’s website.  A replay will be available for 90 days. Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.

  • GlobeNewswire3 months ago

    Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2019) in Copenhagen, Denmark

    NEWTOWN, Pa., May 06, 2019 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule.

  • GlobeNewswire4 months ago

    Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Company will be presenting at the 2019 HCW Global Life Sciences Conference at the Grosvenor House/JW Marriott Hotel in Mayfair, London.  Dr. Steven Fruchtman, President & CEO, will present at the conference and meet with investors. Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells. It is frequently associated with the presence of blasts or leukemic cells in the marrow.  This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ONTX earnings conference call or presentation 26-Mar-19 1:00pm GMT

    Full Year 2018 Onconova Therapeutics Inc Earnings Call

  • GlobeNewswire4 months ago

    Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results

    NEWTOWN, Pa., March 26, 2019 -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule.

  • GlobeNewswire4 months ago

    Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes

    Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer today announced that it has surpassed the 75 percent enrollment milestone in its pivotal Phase 3 trial of rigosertib for the potential treatment of high-risk myelodysplastic syndromes (HR-MDS), a study known as INSPIRE. “We are pleased to have passed the 75 percent completion of enrollment milestone and are on track with our anticipated timeline for completion of accrual to the INSPIRE study in the second half of 2019,” said Dr. Richard Woodman, Onconova’s Chief Medical Officer and Senior Vice President of Research & Development. Dr. Steven M. Fruchtman, President and CEO of Onconova, stated, “Clinical execution including completing our INSPIRE study remains our top priority.

  • GlobeNewswire4 months ago

    Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will release its year-end 2018 financial results on Tuesday, March 26, 2019, before the market opens.  Management will host a conference call on Tuesday, March 26, 2019, at 9:00 a.m. Eastern Time to discuss these results and provide an update on its pipeline programs.  Interested parties may access the call by dialing toll-free (855) 428-5741 from the U.S. or (210) 229-8823 internationally and using conference ID 1878978. Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.

  • GlobeNewswire4 months ago

    Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will participate in the 31st Annual ROTH Conference to be held March 17-19, 2019 at the Ritz Carlton Laguna Niguel in Orange County, CA. Steven M. Fruchtman, MD, President & CEO, and Mark Guerin, CFO, will attend the conference and be available to meet with investors.  Dr. Fruchtman will also participate on a panel to discuss myeloid diseases on Monday, March 18th, from 3:00-4:00p. Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS).  Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.

  • GlobeNewswire6 months ago

    Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City

    Onconova Therapeutics, Inc. (ONTX), Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at the BIO CEO & Investor Conference February 11-12, 2019. Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS).  Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which the Company believes blocks cellular signaling by targeting RAS effector pathways.  Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.

  • GlobeNewswire6 months ago

    Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City

    Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced it will host a KOL breakfast for security analysts and institutional investors on Thursday, February 7, 2019, in New York City. The event will include presentations by Lewis Silverman, MD, Associate Professor of Medicine and Director of the Translational Research Center for the Myelodysplastic Syndrome in the Division of Hematology/Oncology/Tisch Cancer Institute and Rajwanth Veluswamy, MD, MSCR, Assistant Professor of Medicine, Thoracic Oncology, Tisch Cancer Institute, Institute for Translational Epidemiology, Icahn School of Medicine, Mount Sinai Health System.

  • GlobeNewswire6 months ago

    Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL

    Onconova Therapeutics, Inc. (ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Steven M. Fruchtman, President & CEO, will present a company overview at NobleCON15, Noble Capital Markets' 15th annual small cap and emerging growth investor conference being held January 28th and 29th at the W Hotel in Fort Lauderdale, Florida. A webcast of the presentation will be available at the link below and on Onconova's website (https://investor.onconova.com/events-and-presentations) a day after the event. Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS).  Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which the Company believes blocks cellular signaling by targeting RAS effector pathways.

  • Bucks County biopharm firm names new CEO
    American City Business Journals6 months ago

    Bucks County biopharm firm names new CEO

    The cancer therapy-focused company promoted from within when appointing a new CEO to take over the post previously held by a co-founder.

  • GlobeNewswire6 months ago

    Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced the appointment of Dr. Steven Fruchtman as Chief Executive Officer and a member of the Board of Directors, effective immediately. Dr. Fruchtman has served as President of Onconova since June 2018, and originally joined the Company in January 2015 as Chief Medical Officer.

  • GlobeNewswire7 months ago

    Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)

    SPA submitted to the FDA before year-end 2018, marking achievement of a key regulatory milestoneAdvancement of this Phase 3 program, in treatment-naïve higher risk first-line.

  • GlobeNewswire7 months ago

    Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Management will meet Investors and potential partners at the 2019 China Focus event, and during the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. Meetings can be scheduled by contacting Suzanne Hutchison (shutchison@onconova.us). Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS).  Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which the Company believes blocks cellular signaling by targeting RAS effector pathways.  Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.

  • GlobeNewswire7 months ago

    Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Mr. Abraham “Avi” Oler has joined Onconova’s management team as Vice President, Corporate Development and General Counsel.  Mr. Oler will be primarily responsible for business development, investor relations, and legal affairs of the Company. To help further advance Rigosertib, the Company’s Phase 3 candidate for MDS, Mr. Oler’s focus will be on forging new collaborations in additional geographies.  Rigosertib is currently partnered with SymBio Pharmaceuticals for Japan and Korea, and with Pint Pharma for Latin America.  Information about partnering opportunities can be obtained via e-mail at bd@onconova.us or via the Company’s website: https://www.onconova.com/partnering.

  • GlobeNewswire8 months ago

    Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting

    Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylating agent (HMA) naïve patients, including Complete Remission (CR) rate of.

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT

    Q3 2018 Onconova Therapeutics Inc Earnings Call

  • GlobeNewswire8 months ago

    Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018

    Conference Call Today at 9:00 a.m. Eastern Time NEWTOWN, Pa., Nov. 13, 2018 -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on.